leisure time -WSS

leisure time

author：fashion 2025-09-29 21:26:45 - browse：11

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

WSS

Chronically ill young patients struggle to find fertility info

People with mental disorders often marry others with same

Bird flu reported in person exposed to presumably infected cattle

Harvard scientists, with Google, unveil the most detailed brain map ever

3 medical device trends to watch in 2024

GSK Flovent asthma inhalers replaced by authorized generics

leisure time

leisure time

knowledge

Medical records are filled with copy

Medicare Advantage 2025 payments will dip, Biden administration says

Medical leaders decry Supreme Court decision on affirmative action

Goldman Sachs launches $650M fund for life science investments

Novavax promises a turnaround & Lilly roils the obesity market

Chronically ill young patients struggle to find fertility info

Tori Bowie and the unacceptable rates of Black maternal death

3 trends to watch in health tech's hiring outlook for 2024

Medicare details structure of new drug price negotiation program

Alzheimer's risk factor APOE4 may be a distinct form of the disease

explore

Four alarming medical procedures we’re glad history forgot

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Multiple sclerosis has subtypes with different best treatments: study

Insurer loopholes limit power of law against surprise medical bills

Harvard scientists, with Google, unveil the most detailed brain map ever

Multiple sclerosis has subtypes with different best treatments: study

Wikipedia

hotspot

explore

Wikipedia